Neoadjuvant and Adjuvant Surgical Interventions in Oncology: Optimizing Treatment Pathways
Abstract
The advancement of cancer treatment has seen significant progress through the integration of neoadjuvant and adjuvant therapies, particularly within the realm of surgical oncology. This literature review follows a systematic approach using PRISMA guidelines, analyzing studies from databases such as PubMed, Google Scholar, Scopus, and Web of Science. The review examines the historical progression, current practices, and future directions of multimodal approaches, focusing on the synergistic benefits of surgery, drug development, targeted therapies, and technological innovations. Neoadjuvant interventions, designed to shrink tumors preoperatively, enhance surgical outcomes by improving resectability, while adjuvant therapies, administered postoperatively, aim to eliminate residual disease and reduce recurrence risk. Findings from clinical trials and case studies highlight improved survival rates, increased tumor resectability, and enhanced patient outcomes through the combination of these therapies. Additionally, the review emphasizes the crucial role of personalized medicine, molecular profiling, and emerging surgical technologies in refining treatment pathways. As the landscape of cancer care evolves, optimizing treatment sequencing and tailoring therapies to individual tumor profiles will be essential for maximizing therapeutic efficacy and improving patient prognosis.
Keywords: Neoadjuvant Therapy, Adjuvant Surgical Intervention, Surgical Oncology, Multimodal Cancer Treatment, Targeted Cancer Therapy.
Full Text:
PDFReferences
Biesinger, M., Eicken, N., Varga, A., Weber, M., Brndiar, M., Erd, G., et al., 2022, Lymph but Not Blood Vessel Invasion Is Independent Prognostic in Lung Cancer Patients Treated by VATS-Lobectomy and Might Represent a Future Upstaging Factor for Early Stages, Cancers, 14(8), 1893. CrossRef
Bosset, J.F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., et al., 2006, Chemotherapy with preoperative radiotherapy in rectal cancer, The New England Journal of Medicine, 355(11), 1114–1123. CrossRef
Caruso, M., Stanzione, A., Prinster, A., Pizzuti, L. M., Brunetti, A., Maurea, S., and Mainenti, P.P., 2023, Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases, World Journal of Gastroenterology, 29(3), 521–535. CrossRef
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A.C., Raoul, J.L., et al., 2018, FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, The New England Journal of Medicine, 379(25), 2395–2406. CrossRef
Current Controversies in the Management of Biochemical Failure in Prostate Cancer, 2012, Hematology & Oncology, November. Available at: https://www.hematologyandoncology.net/archives/november-2012/current-controversies-in-the-management-of-biochemical-failure-in-prostate-cancer/(Accessed 3 February 2025).
DeMichele, A., Yee, D., Berry, D.A., Albain, K.S., Benz, C.C., Boughey, J., et al., 2015, The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer, Clinical Cancer Research, 21(13), 2911–2915. CrossRef
Feng, X., Yang, J., Laine, A.F., and Angelini, E.D., 2017, Discriminative Localization in CNNs for Weakly-Supervised Segmentation of Pulmonary Nodules, Lecture Notes in Computer Science, 568–576. CrossRef
Forde, P.M., Chaft, J.E., Smith, K.N., Anagnostou, V., Cottrell, T.R., Hellmann, M.D., et al., 2018, Neoadjuvant PD-1 Blockade in Resectable Lung Cancer, New England Journal of Medicine/The New England Journal of Medicine, 378(21), 1976–1986. CrossRef
Forde, P.M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M.M., et al., 2022, Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer, The New England Journal of Medicine, 386(21), 1973–1985. CrossRef
Globus, O., Greenhouse, I., Sella, T., and Gal-Yam, E.N., 2023, The neoadjuvant systemic treatment of early breast cancer: a narrative review, Annals of Breast Surgery, 7, 39. CrossRef
Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rödel, C., Cervantes, A., et al., 2017, Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of oncology : official journal of the European Society for Medical Oncology, 28(suppl_4), iv22–iv40. CrossRef
Holzbeierlein, J., Bixler, B.R., Buckley, D.I., Chang, S.S., Holmes, R.S., James, A.C., et al., 2024, Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024), The Journal of urology, 212(1), 3–10. CrossRef
Hortobagyi, G.N., Ames, F.C., Buzdar, A.U., Kau, S.W., McNeese, M.D., Paulus, D., et al., 1988, Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy, Cancer, 62(12), 2507–2516. CrossRef
IEEE Robotics and Automation Letters publication information, 2019, IEEE Robotics & Automation Letters, 4(4), C2. CrossRef
Janjigian, Y.Y., Kawazoe, A., Yañez, P., Li, N., Lonardi, S., Kolesnik, O., et al., 2021, The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2- positive gastric cancer, Nature, 600(7890), 727–730. CrossRef
Kang, J., Zhang, C., and Zhong, W.Z., 2021, Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art, Cancer communications (London, England), 41(4), 287–302. CrossRef
Keung, E.Z., Ukponmwan, E.U., Cogdill, A.P., and Wargo, J.A., 2018, The Rationale and Emerging Use of Neoadjuvant Immune Check¬point Blockade for Solid Malignancies, Annals of surgical oncology, 25(7), 1814–1827. CrossRef
Khazov, P.A., Maystrenko, A.D., Gurschenkov, A.V., and Shvarts, E.Y., 2021, Open-heart surgery in elderly patients: short-term vs. long-term effects, Saratov Medical Journal, 2(4), e0405. CrossRef
Laina, I., Rieke, N., Rupprecht, C., Vizcaíno, J.P., Eslami, A., Tombari, F. and Navab, N., 2017, Concurrent Segmentation and Localization for Tracking of Surgical Instruments, arXiv preprint arXiv:1703.10701. Available at: https://arx¬iv.org/abs/1703.10701 (Accessed: 3 February 2025). CrossRef
Li, J., Tang, T., Zong, H., Wu, E., Zhao, J., Wu, R., et al., 2024, Intelligent medicine in focus: the 5 stages of evolution in robot-assisted surgery for prostate cancer in the past 20 years and future implications, Military Medical Research, 11(1), 58. CrossRef
Lim, J., Auerbach, M., MacLean, B., Al-Sharea, A., and Richards, T., 2023, Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials, Current oncology (Toronto, Ont.), 30(9), 7836–7851. CrossRef
Liu, B., Zhou, H., Tan, L., Siu, K.T.H., and Guan, X., 2024, Exploring treatment options in cancer: Tumor treatment strategies, Signal Transduction and Targeted Therapy, 9(1), 175. CrossRef
Liu, J., Blake, S.J., Yong, M.C., Harjunpää, H., Ngiow, S.F., Takeda, K., et al., 2016, Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease, Cancer discovery, 6(12), 1382–1399. CrossRef
Menzies, A.M., Scolyer, R.A., and Long, G.V., 2021, Neoadjuvant Immunotherapy in Melanoma-The New Frontier, Clinical cancer research: an official journal of the American Association for Cancer Research, 27(15), 4133–4135. CrossRef
Methodist Healthcare (n.d.), Minimally Invasive Surgery, Available at: https://www.sahealth. com/specialties/surgery/minimally-inva¬sive-surgery (Accessed: 3 February 2025). Link
Miao, S., Piat, S., Fischer, P., Tuysuzoglu, A., Mewes, P., Mansi, T., and Liao, R., 2017, Dilated FCN for Multi-Agent 2D/3D Medical Image Registration, arXiv preprint arXiv:1712.01651. Available at: https://arxiv.org/abs/1712.01651 (Accessed: 3 February 2025). Link
Min, L., Liu, N., Zhou, Y., and Niu, Z., 2022, 1220P Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy, Annals of Oncology, 33, S1106. CrossRef
National Cancer Institute, 2024, FDA Approves Alectinib for ALK-Positive Lung Cancer, Cancer. gov, 8 May. Available at: https://www.cancer. gov/news-events/cancer-currents-blog/2024/fda-alectinib-lung-cancer-alk-positive (Accessed: 3 February 2025). Link
Negrut, R.L., Cote, A., Caus, V.A. and Maghiar, A.M., 2024, Systematic Review and Meta-Analysis of Laparoscopic versus Robotic-Assisted Surgery for Colon Cancer: Efficacy, Safety, and Outcomes—A Focus on Studies from 2020–2024, Cancers, 16(8), 1552. CrossRef
Nema, S., and Vachhani, L., 2022, Surgical instrument detection and tracking technologies: Automating dataset labeling for surgical skill assessment, Frontiers in Robotics and AI, 9. CrossRef
Nevola, R., Delle Femine, A., Rosato, V., Kondili, L.A., Alfano, M., Mastrocinque, D., et al., 2023, Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?, Cancers, 15(11), 2950. CrossRef
O'Donnell, J.S., Hoefsmit, E.P., Smyth, M.J., Blank, C.U., and Teng, M.W.L., 2019, The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment, Clinical cancer research : an official journal of the American Association for Cancer Research, 25(19), 5743–5751. CrossRef
Quezada-Diaz, F.F., and Smith, J.J., 2022, Neoadjuvant Therapy for Rectal Cancer, Surgical oncology clinics of North America, 31(2), 279–291. CrossRef
Sanglier, T., Ross, R., Klein-Panneton, K., Poppe, R., Antao, V., Mamounas, E.P., and Cain, H., 2022, The impact of neoadjuvant treatment (NAT) on surgery in early breast cancer (EBC): A real-world data study, Journal of Clinical Oncology, 40(16_suppl), e12609. CrossRef
Schmid, P., Cortes, J., Dent, R., Pusztai, L., Mcarthur, H., Kümmel, S., et al., 2022, Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer, New England Journal of Medicine/the New England Journal of Medicine, 386(6), 556–567. CrossRef
Shapiro, J., van Lanschot, J.J.B., Hulshof, M.C.C.M., van Hagen, P., van Berge Henegouwen, M.I., Wijnhoven, B.P.L., et al., 2015, Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial, The Lancet. Oncology, 16(9), 1090–1098. CrossRef
Shen, Z., Han, X., Xu, Z., and Niethammer, M. 2019, Networks for Joint Affine and Non-parametric Image Registration, arXiv.org. https://arxiv. org/abs/1903.08811. Link
Siegel, R.L., Miller, K.D., and Jemal, A., 2018, Cancer statistics, 2018, CA: a cancer journal for clinicians, 68(1), 7–30. CrossRef
Siegel, R.L., Miller, K.D., and Jemal, A., 2020, Cancer statistics, 2020, CA: a cancer journal for clinicians, 70(1), 7–30. CrossRef
Small, C., and Laycock, H., 2020, Acute postoperative pain management, British Journal of Surgery, 107(2), e70–e80. CrossRef
Smith, H.G., Nilsson, P.J., Shogan, B.D., Harji, D., Gambacorta, M.A., Romano, A., et al., 2024, Neoadjuvant treatment of colorectal cancer: comprehensive review, BJS Open, 8(3), zrae038. CrossRef
Thomas, D., and Bello, D.M., 2021, Adjuvant immunotherapy for melanoma, Journal of surgical oncology, 123(3), 789–797. CrossRef
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., et al., 2002, Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer, The New England journal of medicine, 347(16), 1227–1232. CrossRef
Versluis, J.M., Long, G.V., and Blank, C.U., 2020, Learning from clinical trials of neoadjuvant checkpoint blockade, Nature medicine, 26(4), 475–484. CrossRef
Wu, Y.L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., et al., 2020, Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer, The New England journal of medicine, 383(18), 1711–1723. CrossRef
Yu, J.X., Hodge, J.P., Oliva, C., Neftelinov, S.T., Hubbard-Lucey, V.M., and Tang, J., 2019, Trends in clinical development for PD-1/PD-L1 inhibitors, Nature Reviews. Drug Discover/Nature Reviews. Drug Discovery, 19(3), 163–164. CrossRef
Zeng, H., Chen, W., Zheng, R., Zhang, S., Ji, J.S., Zou, X., et al., 2018, Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries, The Lancet. Global health, 6(5), e555–e567. CrossRef
DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev15iss3pp237-250
Copyright (c) 2024 Indonesian Journal of Cancer Chemoprevention
Indexed by:
Indonesian Society for Cancer Chemoprevention
